Diagnosing and managing postherpetic neuralgia

Drugs and Aging

Volumn 29, Issue 11, 2012, Pages 863-869

  Nalamachu, Srinivas ^b   Morley Forster, Patricia ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CAPSAICIN; DESIPRAMINE; GABAPENTIN; IMIPRAMINE; LIDOCAINE; METHADONE; MORPHINE; NORTRIPTYLINE; OXYCODONE; PREGABALIN; TRAMADOL; VARICELLA ZOSTER VACCINE;

ACUTE DISEASE; APPLICATION SITE REACTION; ARTICLE; BRACHIAL PLEXUS; COMORBIDITY; DAILY LIFE ACTIVITY; DERMATOME; DISEASE SEVERITY; DRUG EXPOSURE; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; MEDICAL HISTORY; MONOTHERAPY; PHYSICAL EXAMINATION; POLYPHARMACY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RASH; RISK FACTOR; SLEEP; SYSTEMIC THERAPY;

ANALGESICS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; NEURALGIA, POSTHERPETIC;

EID: 84874622955     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0014-3     Document Type: Article

References (46)

1. Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(3 Suppl):21-6.
2. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274-80.
3. Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134-42.
4. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-9. (Pubitemid 350060129)
5. Ragozzino MW, Melton LJ 3rd, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61(5):310-6. (Pubitemid 12031812)
6. Chen N, Li Q, Zhang Y, et al. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2011;3:CD007795.
7. ® (zoster vaccine live): US prescribing information. Whitehouse Station, NJ: Merck & Co., Inc., 2011.
8. Oxman MN, Levin MJ, Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197(Suppl 2):S228-36. (Pubitemid 351590176)
9. Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010;152(9):545-54.
10. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922-8.
11. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280-8. (Pubitemid 46717289)
12. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(2):64.
13. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
14. Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63(6):959-65. (Pubitemid 39287901)
15. Dworkin RH, Jensen MP, Gammaitoni AR, et al. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain. 2007;8(2):118-26. (Pubitemid 46186157)
16. Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. London, UK: National Institute for Health and Clinical Excellence; 2011 February. Report No.: NICE clinical guideline 59.
17. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; (2):CD006866.
18. Chen SM, Chen JT, Kuan TS, et al. Myofascial trigger points in intercostal muscles secondary to herpes zoster infection of the intercostal nerve. Arch Phys Med Rehabil. 1998;79(3):336-8. (Pubitemid 28207124)
19. McElveen WA. Postherpetic neuralgia differential diagnoses. http://emedicine.medscape.com/article/1143066-overview. Accessed 11 May 2011.
20. Baron R, Tolle TR, Gockel U, et al. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain. 2009;146(1-2):34-40.
21. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-51. (Pubitemid 350051570)
22. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13-21. (Pubitemid 46744774)
23. Baron R. Neuropathic pain: a clinical perspective. Handb Exp Pharmacol. 2009;194:3-30.
24. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118(3):289-305. (Pubitemid 41752987)
25. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81(12):1372-3.
26. Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; (3):CD007938.
27. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; (3):CD007076.
28. Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010;35(6):639-56.
29. Baron R, Mayoral V, Leijon G, et al. 5 % lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663-76.
30. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of 5 % lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009;29(4):231-41.
31. Binder A, Bruxelle J, Rogers P, et al. Topical 5 % lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29(6):393-408.
32. Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5 % lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin. 2010;26(7):1607-19.
33. Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5 % lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009;25(5):1295-305.
34. Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):e164. (Pubitemid 46179274)
35. Campbell BJ, Rowbotham M, Davies PS, et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002;91(5):1343-50. (Pubitemid 34651196)
36. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5 % with extended dosing. Ann Pharmacother. 2002;36(2):236-40. (Pubitemid 34126813)
37. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5 %, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003;43(2):111-7. (Pubitemid 36125935)
38. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59(7):1015-21.
39. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81(1-2):135-45. (Pubitemid 29199909)
40. Backonja MM, Malan TP, Vanhove GF, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11(4):600-8.
41. Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21(2 Pt 1):265-70. (Pubitemid 19195889)
42. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15(3):510-26. (Pubitemid 23194627)
43. Noto C, Pappagallo M, Szallasi A. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr Opin Investig Drugs. 2009;10(7):702-10.
44. Irving GA, Backonja M, Rauck R, et al. NGX-4010, a capsaicin 8 % dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012;28(2):101-7.
45. ® (capsaicin 8 % patch): US prescribing information. San Mateo, CA: NeurogesX, Inc., 2009.
46. Vorobeychik Y, Gordin V, Mao J, et al. Combination therapy for neuropathic pain: a review of current evidence. CNS Drugs. 2011;25(12):1023-34.